Mechanism of Action:

​

Tesamorelin binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile growth hormone release. This activation enhances IGF-1 signaling, which supports anabolic processes, lipolysis, and tissue regeneration, while also modulating body composition.

​

Clinical Relevance & Potential Outcomes:

​

Clinical studies indicate Tesamorelin may support reductions in visceral adipose tissue, improvements in lean body mass, and metabolic regulation, particularly in populations with GH deficiency or age-related metabolic changes. It has been used therapeutically to improve body composition and support metabolic health.

​

Intended Clinical Application:

​

Tesamorelin may be relevant for patients requiring targeted reduction of visceral fat, enhancement of lean body mass, or improvement of metabolic parameters, including those with GH insufficiency or metabolic dysfunction.